etherna, a leading mRNA and lipid nanoparticle (LNP) technology platform company originally founded as a spin-off from VUB, has announced a major milestone in its partnership with US-based Dropshot Therapeutics. Dropshot has officially decided to advance one of its selected targets in renal disease to the clinical stage, successfully validating etherna’s cutting-edge platform technologies.
Moving forward, the collaboration will leverage etherna’s extensive manufacturing capabilities to produce Good Manufacturing Practice (GMP)-grade material for Investigational New Drug (IND) enabling studies, with Phase I clinical trials intended to launch in 2027.
Founded in 2013 based on groundbreaking research at VUB, etherna has evolved into a key strategic partner for the global life sciences industry, supporting innovative RNA therapeutics from early research through to GMP manufacturing.